Genotyping lung cancer linked to better survival

Genetic testing for personalized treatment of lung cancer was associated with improved survival, likely due to getting targeted kinase inhibitors to the right patients, a study showed.

Patients whose tumors were genotyped had 28% better overall survival odds than those who couldn’t get a genetic diagnosis for reasons like limited tissue availability (P=0.002), Roman K. Thomas, MD, of the University of Cologne in Germany, and colleagues found.

For the 75% who could be genotyped, treatment recommendations for genetically-tailored cancer therapy with approved drugs or in clinical trials were given.

The genotyped patients had a median overall survival of 31.6 months compared with 15.1 among those not able to be genotyped, for a multivariate-adjusted hazard ratio of 0.719 (95% confidence interval 0.588-0.879).

Read the full, original story here: Genotyping Lung Cancer Linked to Better Survival

Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: How dangerous COVID mutant strains develop

Infographic: How dangerous COVID mutant strains develop

Sometime in 2019, probably in China, SARS CoV-2 figured out a way to interact with a specific "spike" on the ...

Philip Njemanze: Leading African anti-GMO activist claims Gates Foundation destroying Nigeria

Nigerian anti-GMO activist, physician, and inventor pushes anti-gay and anti-GMO ...

Most Popular

News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend